Ignite Creation Date:
2024-05-06 @ 6:55 PM
Last Modification Date:
2024-10-26 @ 2:57 PM
Study NCT ID:
NCT05833282
Status:
RECRUITING
Last Update Posted:
2023-04-27
First Post:
2023-04-04
Brief Title:
Prognostic Factors and Therapeutic Management of ESBL Enterobacteriaceae in the ICU
Sponsor:
Tourcoing Hospital
Organization:
Tourcoing Hospital
Study Overview
Official Title:
Prognostic Factors and Therapeutic Management of ESBL Enterobacteriaceae in the ICU
Status:
RECRUITING
Status Verified Date:
2023-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
BLSE-REA
Brief Summary:
Multicenter retrospective study conducted in the intensive care units of Tourcoing Roubaix and Lille hospitals Patients hospitalized in the ICU with EBLSE bacteremia within 24 hours before or during their stay in the ICU will be selected from microbiology laboratory data Patient demographics and clinical data will be collected from the medical record Microbiological results will be collected from the laboratory data
Detailed Description:
INCLUSION CRITERIA - Patients admitted to the ICU with EBLSE bacteremia within 24 hours before or during their stay in the ICU
PRIMARY ENDPOINT
- The primary endpoint is 30-day mortality
PRIMARY ENDPOINT
- The primary endpoint is 30-day mortality
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None